Drug updated on 3/28/2024
| Dosage Form | Capsule (oral: 0.25 mg, 0.5 mg, 0.75 mg, 1 mg) |
| Drug Class | Poly (ADP-ribose) polymerase (PARP) inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.
Summary
- Talazoparib (Talzenna) is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.
- According to a systematic review and meta-analysis, talazoparib was associated with an increased risk of hematological adverse events such as all-grade anemia, thrombocytopenia, and neutropenia compared to placebo and/or other non-PARPi treatments in prostate cancer trials.
- In another study comparing different PARP inhibitors including talazoparib in BRCA-positive metastatic castration-resistant prostate cancer patients, it was found that these drugs had similar efficacy in terms of progression-free survival (PFS) and overall survival (OS).
- A comparison between single-agent poly ADP-ribose polymerase inhibitors like talazoparib showed no significant difference in progression-free survival or overall survival among patients with BRCA-mutated HER2-negative metastatic or advanced breast cancer.
- The safety profile analysis revealed that while serious adverse events were comparable across approved PARP inhibitors including talazoparib, there were significant differences observed regarding interruption of treatment due to adverse effects where talazoparib posed higher risks than others.
- This information has been derived from 10 Systematic Reviews / Meta-Analyses documents focusing on the use of Talzenna for treating various types of cancers primarily involving mutations in the BRCA gene sequence leading to aggressive forms like HER2 negative locally advanced/metastatic breast cancers among adults.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Talzenna (talazoparib) Prescribing Information. | 2021 | Pfizer Inc., New York, NY |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO Guideline Update. | 2021 | Journal of Clinical Oncology |
| Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology guideline. | 2020 | Journal of Clinical Oncology |